Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways

Mark A. Birrell, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Elizabeth L. Hardaker, Saleem Haj-Yahia and Maria G. Belvisi
Journal of Pharmacology and Experimental Therapeutics March 2006, 316 (3) 1318-1327; DOI: https://doi.org/10.1124/jpet.105.093310
Mark A. Birrell
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sissie Wong
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerryn McCluskie
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthew C. Catley
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth L. Hardaker
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Saleem Haj-Yahia
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria G. Belvisi
Respiratory Pharmacology Group, Airway Diseases, Imperial College School of Medicine, National Heart and Lung Institute, Chelsea, London, United Kingdom (M.A.B., S.W., K.M., M.C.C., E.L.H., M.G.B.); and Royal Brompton and Harefield Hospital, London, United Kingdom (S.H.-Y.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The exact role of p38 mitogen-activated protein kinase (MAPK) in the expression of inflammatory cytokines is not clear; it may regulate transcriptionally, post-transcriptionally, translationally, or post-translationally. The involvement of one or more of these mechanisms has been suggested to depend on the particular cytokine, the cell type studied, and the specific stimulus used. Interpretation of some of the published data is further complicated by the use of inhibitors such as 4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole (SB 203580) used at single, high concentrations. The aim of this study was to determine the impact of two second-generation p38 MAPK inhibitors on the expression of a range of inflammatory cytokines at the gene and protein levels in human cultured cells. Similar assessment of the impact of these compounds on inflammatory cytokine expression in a preclinical in vivo model of airway inflammation was performed. The results in THP-1 cells and primary airway macrophages clearly show that protein expression is inhibited at much lower concentrations of inhibitor than are needed to impact on gene expression. In the rodent model, both compounds, at doses that cause maximal inhibition of cellular recruitment, inhibit tumor necrosis factor α (TNFα) protein production without impacting on nuclear factor κB pathway activation or TNFα gene expression. In summary, the data shown here demonstrate that, although at high compound concentrations there is some level of transcriptional regulation, the predominant role of p38 MAPK in cytokine production is at the translational level. These data question whether the effect of p38 inhibitors on gene transcription is related to their potential therapeutic role as anti-inflammatory compounds.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 316 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 316, Issue 3
1 Mar 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways

Mark A. Birrell, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Elizabeth L. Hardaker, Saleem Haj-Yahia and Maria G. Belvisi
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1318-1327; DOI: https://doi.org/10.1124/jpet.105.093310

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Second-Generation Inhibitors Demonstrate the Involvement of p38 Mitogen-Activated Protein Kinase in Post-Transcriptional Modulation of Inflammatory Mediator Production in Human and Rodent Airways

Mark A. Birrell, Sissie Wong, Kerryn McCluskie, Matthew C. Catley, Elizabeth L. Hardaker, Saleem Haj-Yahia and Maria G. Belvisi
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1318-1327; DOI: https://doi.org/10.1124/jpet.105.093310
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lipopolysaccharide Induces Epithelium- and Prostaglandin E2-Dependent Relaxation of Mouse Isolated Trachea through Activation of Cyclooxygenase (COX)-1 and COX-2
  • Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship
  • Protease-Activated Receptor-2 Peptides Activate Neurokinin-1 Receptors in the Mouse Isolated Trachea
Show more INFLAMMATION AND IMMUNOPHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics